Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

6.4: Protein Synthesis

Transcription Transcription is the first part of protein synthesis: DNA → RNA . It is the transfer of genetic instructions in DNA to mRNA. Transcription happens in the nucleus of the cell. During transcription, a strand of mRNA is made that is complementary to

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Transcription

Transcription is the first part of protein synthesis: DNA → RNA . It is the transfer of genetic instructions in DNA to mRNA. Transcription happens in the nucleus of the cell. During transcription, a strand of mRNA is made that is complementary to a strand of DNA called a gene. A gene can easily be identified from the DNA sequence. A gene contains the basic three regions, promoter, coding sequence (reading frame), and terminator. There are more parts of a gene which are illustrated in Figure \(\PageIndex{3}\).

Figure \(\PageIndex{3}\): The major components of a gene. 1. promoter, 2. transcription initiation, 3. 5' upstream untranslated region, 4. translation start codon site, 5. protein-coding sequence, 6. translation stop codon region, 7. 3' downstream untranslated region, and 8. terminator.

Steps of Transcription

Transcription takes place in three steps, called initiation, elongation, and termination. The steps are illustrated in Figure \(\PageIndex{4}\).

  • Initiation is the beginning of transcription. It occurs when the enzyme RNA polymerase binds to a region of a gene called the promoter . This signals the DNA to unwind so the enzyme can “read” the bases in one of the DNA strands. The enzyme is ready to make a strand of mRNA with a complementary sequence of bases. The promoter is not part of the resulting mRNA
  • Elongation is the addition of nucleotides to the mRNA strand.
  • Termination is the ending of transcription. As RNA polymerase transcribes the terminator, it detaches from DNA. The mRNA strand is complete after this step. Figure \(\PageIndex{4}\): Transcription occurs in the three steps - initiation, elongation, and termination

Processing mRNA

In eukaryotes, the new mRNA is not yet ready for translation. At this stage, it is called pre-mRNA, and it must go through more processing before it leaves the nucleus as mature mRNA. The processing may include the addition of a 5' cap, splicing, editing, and 3' polyadenylation (poly-A) tail. These processes modify the mRNA in various ways. Such modifications allow a single gene to be used to make more than one protein. See Figure \(\PageIndex{5}\) as you read below:

  • 5' cap protects mRNA in the cytoplasm and helps in the attachment of mRNA with the ribosome for translation.
  • Splicing removes introns from the protein-coding sequence of mRNA. Introns are regions that do not code for the protein. The remaining mRNA consists only of regions called exons that do code for the protein.
  • Editing changes some of the nucleotides in mRNA. For example, a human protein called APOB, which helps transport lipids in the blood, has two different forms because of editing. One form is smaller than the other because editing adds an earlier stop signal in mRNA.
  • Polyadenylation adds a “tail” to the mRNA. The tail consists of a string of As (adenine bases). It signals the end of mRNA. It is also involved in exporting mRNA from the nucleus, and it protects mRNA from enzymes that might break it down.

Figure \(\PageIndex{5}\): Splicing removes introns from mRNA. Mature mRNA is translated to protein.

Translation

The translation is the second part protein synthesis ( RNA --> Protein ) is the process in which the genetic code in mRNA is read to make a protein. The translation is illustrated in Figure \(\PageIndex{6}\). After mRNA leaves the nucleus, it moves to a ribosome, which consists of rRNA and proteins. Translation happens on the ribosomes floating in the cytosol, or on the ribosomes attached to the rough endoplasmic reticulum. The ribosome reads the sequence of codons in mRNA, and molecules of tRNA bring amino acids to the ribosome in the correct sequence. To understand the role of tRNA, you need to know more about its structure. Each tRNA molecule has an anticodon for the amino acid it carries. An anticodon is complementary to the codon for an amino acid. For example, the amino acid lysine has the codon AAG, so the anticodon is UUC. Therefore, lysine would be carried by a tRNA molecule with the anticodon UUC. Wherever the codon AAG appears in mRNA, a UUC anticodon of tRNA temporarily binds. While bound to mRNA, tRNA gives up its amino acid. With the help of rRNA, bonds form between the amino acids as they are brought one by one to the ribosome, creating a polypeptide chain. The chain of amino acids keeps growing until a stop codon is reached. Ribosomes, which are just made out of rRNA (ribosomal RNA) and protein, have been classified as ribozymes because the rRNA has enzymatic activity. The rRNA is important for the peptidyl transferase activity that bonds amino acids. Ribosomes have two subunits of rRNA and protein. The large subunit has three active sites called E, P, and A sites. These sites are important in the catalytic activity of ribosomes. Just as with mRNA synthesis, protein synthesis can be divided into three phases: initiation, elongation, and termination. In addition to the mRNA template, many other molecules contribute to the process of translation, such as ribosomes, tRNAs, and various enzymatic factors Translation Initiation: The small subunit binds to a site upstream (on the 5' side) of the start of the mRNA. It proceeds to scan the mRNA in the 5'-->3' direction until it encounters the START codon (AUG). The large subunit attaches and the initiator tRNA, which carries methionine (Met), binds to the P site on the ribosome. Translation Elongation: The ribosome shifts one codon at a time, catalyzing each process that occurs in the three sites. With each step, a charged tRNA enters the complex, the polypeptide becomes one amino acid longer, and an uncharged tRNA departs. The energy for each bond between amino acids is derived from GTP, a molecule similar to ATP. Briefly, the ribosomes interact with other RNA molecules to make chains of amino acids called polypeptide chains, due to the peptide bond that forms between individual amino acids. Inside the ribosome, three sites participate in the translation process, the A, P, and E sites. Amazingly, the E. coli translation apparatus takes only 0.05 seconds to add each amino acid, meaning that a 200-amino acid polypeptide could be translated in just 10 seconds. Translation Termination : Termination of translation occurs when a stop codon (UAA, UAG, or UGA) is encountered (see Figure \(\PageIndex{7}\). When the ribosome encounters the stop codon, the growing polypeptide is released with the help of various releasing factors and the ribosome subunits dissociate and leave the mRNA. After many ribosomes have completed translation, the mRNA is degraded so the nucleotides can be reused in another transcription reaction.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01HOW ARE ANTINEOPLASTIC PROTEIN SYNTHESIS INHIBITORS USED?

Antineoplastic protein synthesis inhibitors are indicated for the treatment of chronic or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

Source: www.rxlist.com ↗
02Could you discuss any ongoing or future research projects that you are particularly excited about in the field of axon biology and sncRNAs?

Certainly. We're keenly exploring extracellular vesicles as mediums for cells to communicate. These cell made vesicles often carry microRNAs and other non-coding RNAs, presenting a unique avenue to understand how neurons modulate their environment, which is especially interesting in neurological conditions. We are exploring extracellular vesicles as these tools with which cells can communicate and transfer gene expression patterns. And we're looking at, for example, how early life brain tumours such as medulloblastoma can impact neuron development and activity and how this can affect later life pain processing and neurological conditions. This has been possible via funding from the Medical Research Foundation, which supported a big collaboration between the labs of Gareth Hathway, Beth Coyle, Vicky James, Anna Grabowska and myself in Nottingham.

Source: www.news-medical.net ↗
comparison

Local vs Systemic IGF-1: The Research Design Implication

A key experimental consideration in IGF-1 LR3 research is the distinction between local intramuscular injection (mimicking locally produced muscle IGF-1) and systemic administration (mimick…

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

Research Design Considerations and Purity Standards

Sermorelin research design requires attention to: (1) dosing frequency — single daily vs twice daily dosing produces substantially different 24-h GH-pulse profiles; 24-h sampling with blood drawn every 20 min (indwelling jugular catheter in unrestrained rats, Culex automated blood sampler or manual serial sampling under minimal stress conditions) followed by pulsatile analysis (Deconvolution algorithm, CLUSTER pulse analysis software, or Pulsar algorithm) quantifies GH pulse frequency, amplitude and half-width as pharmacodynamic endpoints; (2) background GHRH tone — SST infusion (somatostatin 14, 1 µg/kg/min i.v. for 60 min) as a pharmacological tool to suppress endogenous GHRH-primed pituitary responsiveness, allowing sermorelin dose-response to be studied against a defined, controlled GHRHR activation background; (3) sex — GHRH-stimulated GH secretion is sexually dimorphic (males have greater pulsatility amplitude; females have higher basal IGF-1 due to oestrogen-driven hepatic IGF-1 induction), requiring sex-stratified analysis or inclusion of both sexes with appropriate statistical interaction terms. Analytical quality for sermorelin: ≥98% purity by RP-HPLC (C18, 0.1% TFA gradient, UV 220 nm), ESI-MS confirmed molecular mass ([M+H]+ = 3358.9 Da expected), endotoxin ≤1 EU/mg (LAL assay), sterility verified by 14-day thioglycollate broth culture. Reconstitute in sterile 0.9% saline or 0.9% NaCl with 0.1% glacial acetic acid (pH 4.5–5.5); lyophilised formulation preferred for stability at −80°C; avoid repeated freeze-thaw cycles (aliquot to single-use vials at reconstitution). 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Sermorelin for research and laboratory use. View UK stock →

Source: peptideslabuk.com ↗

Studies of Chonluten Peptide in Protein Synthesis and Inflammation Reduction

by Dr. Usman | Sep 7, 2022 | Research Contents: Tripeptides in Bioregulatory Processes Chonluten and Gene Expression in the Lungs Chonluten and the Gastrointestinal Tract References Featured Product

Source: biotechpeptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →